Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-na�
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responder
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
06:02am, Tuesday, 26'th May 2026
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
04:02pm, Tuesday, 19'th May 2026
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura ma
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:00pm, Wednesday, 13'th May 2026
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
12:20am, Wednesday, 13'th May 2026
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology Q1 Earnings Call Highlights
09:10pm, Tuesday, 12'th May 2026
Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
06:16pm, Tuesday, 12'th May 2026
Kura Oncology (KURA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.66 per share a year ago.
Kura Oncology Reports First Quarter 2026 Financial Results
04:02pm, Tuesday, 12'th May 2026
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
09:40am, Tuesday, 12'th May 2026
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
07:30am, Wednesday, 06'th May 2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
Kura Oncology to Report First Quarter 2026 Financial Results
07:30am, Tuesday, 05'th May 2026
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Monday, 04'th May 2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatm
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:01am, Thursday, 30'th Apr 2026
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
08:00am, Friday, 24'th Apr 2026
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
